FY2026 EPS Estimates for Palomar Lifted by DOWLING & PARTN

Key Points

• DOWLING & PARTN raised Palomar’s FY2026 EPS estimate to $8.99 from $8.53, compared with the broader consensus estimate of $9.06.
• Palomar reported quarterly EPS of $2.36, beating expectations by $0.17, while revenue totaled $314.42 million; analysts maintain a “Moderate Buy” consensus rating with a $162.75 price target.
• The company declared a quarterly dividend of $0.45 per share, equivalent to $1.80 annually and a 1.4% yield; insiders have sold 22,050 shares worth approximately $2.88 million over the past 90 days.

Palomar Holdings, Inc. (NASDAQ:PLMR - Free Report) - Investment analysts at DOWLING & PARTN lifted their FY2026 earnings per share estimates for shares of Palomar in a note issued to investors on Friday, August 14th. DOWLING & PARTN analyst N. Iacoviello now anticipates that the company will post earnings of $8.99 per share for the year, up from their prior estimate of $8.53. The consensus estimate for Palomar's current full-year earnings is $9.06 per share.

Palomar (NASDAQ:PLMR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $2.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.17. Palomar had a net margin of 18.61% and a return on equity of 23.28%. The company had revenue of $314.42 million during the quarter, compared to the consensus estimate of $621.52 million. During the same period in the previous year, the firm posted $1.76 earnings per share.

A number of other equities analysts have also recently weighed in on PLMR. Evercore set a $152.00 price objective on shares of Palomar in a research report on Friday, July 10th. Piper Sandler raised their target price on shares of Palomar from $132.00 to $165.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 15th. Zacks Research lowered shares of Palomar from a "strong-buy" rating to a "hold" rating in a report on Friday, May 15th. Keefe, Bruyette & Woods lifted their price target on shares of Palomar from $166.00 to $167.00 and gave the company an "outperform" rating in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Palomar from $150.00 to $167.00 and gave the company an "overweight" rating in a research note on Monday, July 20th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $162.75.

Palomar Price Performance

NASDAQ:PLMR opened at $129.69 on Wednesday. The company has a quick ratio of 0.50, a current ratio of 0.50 and a debt-to-equity ratio of 0.30. Palomar has a 52 week low of $100.81 and a 52 week high of $147.62. The stock's 50-day moving average price is $129.91 and its 200-day moving average price is $123.81. The stock has a market capitalization of $3.41 billion, a PE ratio of 17.43 and a beta of 0.40.

Palomar Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 2nd. Stockholders of record on Wednesday, August 19th will be issued a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Wednesday, August 19th.

Insider Buying and Selling

In other Palomar news, President Jon Christianson sold 6,863 shares of Palomar stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $139.50, for a total value of $957,388.50. Following the transaction, the president directly owned 66,478 shares in the company, valued at approximately $9,273,681. This trade represents a 9.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Timothy Carter sold 480 shares of the business's stock in a transaction that occurred on Sunday, June 28th. The shares were sold at an average price of $124.29, for a total value of $59,659.20. Following the completion of the transaction, the insider directly owned 1,670 shares in the company, valued at approximately $207,564.30. The trade was a 22.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 22,050 shares of company stock worth $2,875,050. Insiders own 3.70% of the company's stock.

Hedge Funds Weigh In On Palomar

Several institutional investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new stake in shares of Palomar in the 4th quarter worth $32,000. Kestra Advisory Services LLC purchased a new stake in Palomar in the 4th quarter valued at approximately $33,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Palomar by 81.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company's stock valued at $40,000 after buying an additional 132 shares during the period. Quantbot Technologies LP acquired a new position in Palomar during the second quarter worth $43,000. Finally, Frazier Financial Advisors LLC purchased a new position in Palomar in the fourth quarter worth $54,000. 90.25% of the stock is owned by institutional investors and hedge funds.

Palomar Company Profile

Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source